The landscape of CNS tumor pathology has evolved rapidly in the past several years. From the earliest histologic descriptions of gliomas to the implementation of cutting edge advanced technology to identify neoplasms by their molecular signature, neuropathology as a field has made great strides towards making personalized medicine a realistic goal. There have been key developments in tumor biomarkers, important updates to CNS tumor classification, and streamlined approaches to current neuropathologic workflow. The evolution of CNS tumor terminology and classification continues to be refined as evidenced by the improved diagnostics and therapeutics offered to patients. The future of neuropathology is based upon maintaining a high standard of academic research combined with excellent medical education and innovation, as well as strong connections between national and international communities with a shared commitment to providing the best possible care to all people.